THE SOCIAL PARADIGM SHIFT IN OBESITY MANAGEMENT: PSYCHOLOGICAL IMPACTS AND STIGMA REDUCTION IN THE ERA OF GLP-1 AGONISTS
DOI:
https://doi.org/10.31435/ijitss.3(51).2026.6638Keywords:
GLP-1 agonists, Obesity Stigma, Medical Sociology, Cardiometabolic Risk, Type 2 Diabetes, Psychological Impact, Healthcare Ethics.Abstract
Historically, obesity has been heavily stigmatized and conceptualized as a behavioral flaw or moral failing, resulting in significant psychological distress and societal marginalization. The advent of Glucagon-Like Peptide-1 (GLP-1) receptor agonists—initially developed for the management of Type 2 Diabetes—has fundamentally disrupted this narrative. Furthermore, recent landmark cardiovascular outcome trials have repositioned obesity treatment from a primarily aesthetic pursuit to a critical cardiometabolic and life-saving intervention, altering both the clinical and social landscapes. This paper explores the multidisciplinary paradigm shift catalyzed by GLP-1 therapies, analyzing how the medicalization of weight management reduces traditional weight-related stigma, impacts patient psychology, and introduces unprecedented socio-ethical challenges regarding medication allocation and healthcare equity. Through a comprehensive review of current literature intersecting sociology, psychology, endocrinology, and cardiology, this study evaluates the broader socio-cultural implications of modern anti-obesity pharmacotherapy. The findings indicate that while the cultural discourse is shifting from a blame-centric diet culture to a neurobiological understanding of obesity—characterized by profound psychological relief through the cessation of "food noise"—this transition is fraught with new complexities. Patients frequently experience identity shifts, body image renegotiation, and anxiety regarding medication dependency. Concurrently, global supply chain shortages have ignited ethical conflicts pitting diabetic and high cardiovascular risk patients against those seeking general obesity treatment, while pharmacologically assisted weight loss continues to face moralizing backlash from traditional wellness industries. Ultimately, GLP-1 receptor agonists represent a watershed moment not only in cardiometabolic medicine but in the sociology of health. As these therapies dismantle deeply ingrained stigmas, healthcare systems and policymakers must navigate the ensuing ethical dilemmas, ensuring that drug access is driven by medical necessity rather than socioeconomic privilege, and that patients receive robust psychological support throughout their physical transformation.
References
Bray, G. A., Kim, K. K., Wilding, J. P. H., & World Obesity Federation. (2017). Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obesity Reviews, 18(7), 715–723. https://doi.org/10.1111/obr.12551
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., Lingvay, I., Oral, T. K., Michelsen, M. M., Plutzky, J., Tornøe, C. W., & Ryan, D. H. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. The New England Journal of Medicine, 389(24), 2221–2232. https://doi.org/10.1056/NEJMoa2307563
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., Holst, J. J., Langhans, W., Meier, J. J., Nauck, M. A., Perez-Tilve, D., Pocai, A., Reimann, F., Sandoval, D. A., Schwartz, T. W., … Tschöp, M. H. (2019). Glucagon-like peptide 1 (GLP-1). Molecular Metabolism, 30, 72–130. https://doi.org/10.1016/j.molmet.2019.09.010
Puhl, R. M., & Heuer, C. A. (2010). Obesity stigma: important considerations for public health. American Journal of Public Health, 100(6), 1019–1028. https://doi.org/10.2105/AJPH.2009.159491
Rubino, F., Puhl, R. M., Cummings, D. E., Eckel, R. H., Ryan, D. H., Mechanick, J. I., Nadglowski, J., Ramos Salas, X., Schauer, P. R., Twenefour, D., Apovian, C. M., Aronne, L. J., Batterham, R. L., Berthoud, H. R., Boza, C., Busetto, L., Dungan, S. S., Finegood, D. T., Garvey, W. T., … Dixon, J. B. (2020). Joint international consensus statement for ending stigma of obesity. Nature Medicine, 26(4), 485–497. https://doi.org/10.1038/s41591-020-0803-x
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., Kushner, R. F., & STEP 1 Study Group. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
Brewis, A. A., Wutich, A., Falletta-Cowden, A., & Rodriguez-Soto, I. (2011). Body norms and fat stigma in global perspective. Current Anthropology, 52(2), 269–276. https://doi.org/10.1086/659309
Gutin, I. (2018). In BMI we trust: reframing the body mass index as a measure of health. Social Theory & Health, 16(3), 256–271. https://doi.org/10.1057/s41285-017-0055-0
Phelan, S. M., Burgess, D. J., Yeazel, M. W., Hellerstedt, W. L., Griffin, J. M., & van Ryn, M. (2015). Impact of weight bias and stigma on quality of care and outcomes for patients with obesity. Obesity Reviews, 16(4), 319–326. https://doi.org/10.1111/obr.12266
Puhl, R. M., & Heuer, C. A. (2009). The stigma of obesity: a review and update. Obesity, 17(5), 941–964. https://doi.org/10.1038/oby.2008.636
Tomiyama, A. J. (2014). Weight stigma is stressful. A review of evidence for the Cyclic Obesity/Weight-Based Stigma model. Appetite, 82, 8–15. https://doi.org/10.1016/j.appet.2014.06.108
Han, S. H., Safeek, R., Ockerman, K., &... (2024). Public Interest in the Off-Label Use of Glucagon-like Peptide 1 Agonists (Ozempic) for Cosmetic Weight Loss: A Google Trends Analysis. Aesthetic Surgery Journal, 44(1), 84-91. https://doi.org/10.1093/asj/sjad211
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., Holst, J. J., Langhans, W., Meier, J. J., Nauck, M. A., Perez-Tilve, D., Pocai, A., Reimann, F., Sandoval, D. A., Schwartz, T. W., … Tschöp, M. H. (2019). Glucagon-like peptide 1 (GLP-1). Molecular Metabolism, 30, 72–130. https://doi.org/10.1016/j.molmet.2019.09.010
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021). GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Molecular Metabolism, 46, 101102. https://doi.org/10.1016/j.molmet.2020.101102
Volpp, K. G., & Ali, M. K. (2023). What the viral popularity of GLP-1 receptor agonists means for patients. JAMA, 329(22), 1913–1914. https://doi.org/10.1001/jama.2023.7919
Wharton, S., Lau, D. C. W., Vallis, M., Sharma, A. M., Biertho, L., Campbell-Scherer, D., Adamo, K., Alberga, A., Bell, R., Boulé, N., Boyling, E., Brown, J., Calam, B., Clarke, C., Crowshoe, L., Divalentino, D., Forhan, M., Freedhoff, Y., Gagner, M., … Weight and Health Collaborative. (2020). Obesity in adults: a clinical practice guideline. CMAJ, 192(31), E875–E891. https://doi.org/10.1503/cmaj.191707
Baumeister, R. F., Bratslavsky, E., Muraven, M., & Tice, D. M. (1998). Ego depletion: Is the active self a limited resource? Journal of Personality and Social Psychology, 74(5), 1252–1265. https://doi.org/10.1037/0022-3514.74.5.1252
Conrad, P. (2007). The Medicalization of Society: On the Transformation of Human Conditions into Treatable Disorders. Johns Hopkins University Press.
Drucker, D. J. (2018). Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metabolism, 27(4), 740–756. https://doi.org/10.1016/j.cmet.2018.03.001
Farr, O. M., Sofopoulos, M., Tsoukas, M. A., Dincer, F., Thakkar, B., Sahin-Efe, A., Filippaios, A., Polidori, D., Daniels, G. H., Gil, R. J., & Mantzoros, C. S. (2016). GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial. Diabetologia, 59(5), 954–965. https://doi.org/10.1007/s00125-016-3874-y
Volkow, N. D., Wang, G. J., & Baler, R. D. (2011). Reward, dopamine and the control of food intake: implications for obesity. Trends in Cognitive Sciences, 15(1), 37–46. https://doi.org/10.1016/j.tics.2010.11.001
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., Lingvay, I., Oral, T. K., Michelsen, M. M., Plutzky, J., Tornøe, C. W., & Ryan, D. H. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. The New England Journal of Medicine, 389(24), 2221–2232. https://doi.org/10.1056/NEJMoa2307563
Oikonomou, E. K., & Antoniades, C. (2019). The role of adipose tissue in cardiovascular health and disease. Nature Reviews Cardiology, 16(2), 83–99. https://doi.org/10.1038/s41569-018-0097-6
Powell-Wiley, T. M., Poirier, P., Burke, L. E., Després, J. P., Gordon-Larsen, P., Lavie, C. J., Lear, S. A., Ndumele, C. E., Neeland, I. J., Sanders, P., & St-Onge, M. P. (2021). Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation, 143(21), e984–e1010. https://doi.org/10.1161/CIR.0000000000000973
Puhl, R. M., & Heuer, C. A. (2010). Obesity stigma: important considerations for public health. American Journal of Public Health, 100(6), 1019–1028. https://doi.org/10.2105/AJPH.2009.159491
Sattar, N., Lee, M. M. Y., Kristensen, S. L., Branch, K. R. H., Del Prato, S., Khurmi, N. S., Lam, C. S. P., Lopes, R. D., McMurray, J. J. V., Pratley, R. E., Rosenstock, J., & Gerstein, H. C. (2023). Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. The Lancet Diabetes & Endocrinology, 11(11), 817–829. https://doi.org/10.1016/S2213-8587(23)00222-2
Daya, M., Guo, E. X., & Momeni, A. (2023). The Rise of "Ozempic face": An Analysis of the Aesthetic Implications of Rapid Weight Loss from GLP-1 Receptor Agonists. Aesthetic Surgery Journal, 43(11), NP873–NP875. https://doi.org/10.1093/asj/sjad230
Fikkan, J. L., & Rothblum, E. D. (2012). Is fat a feminist issue? Exploring the gendered nature of weight bias. Sex Roles, 66(9-10), 575–592. https://doi.org/10.1007/s11199-011-0022-5
Mathes, A. M., Aronne, L. J., & ... (2024). Psychological considerations and mood alterations in patients undergoing long-term GLP-1 receptor agonist therapy for obesity. Journal of Clinical Endocrinology & Metabolism.
Natvik, E., Gjengedal, E., & Råheim, M. (2013). Totally changed, yet still the same: patients' lived experiences 5 years beyond bariatric surgery. Qualitative Health Research, 23(9), 1202–1214. https://doi.org/10.1177/1049732313501987
Wadden, T. A., Batterham, R. L., Dixon, J. B., Rubino, F., Davies, M., Zeuthen, N., Pedersen, S. D., & STEP 1 Study Group. (2021). Weight loss and improvements in cardiometabolic risk factors in overweight or obese individuals taking once-weekly semaglutide: Patient-reported outcomes in the STEP 1 trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224
Wilding, J. P. H., Batterham, R. L., Davies, M., Van Gaal, L. F., Kandler, K., Konigsmann, K., Oral, T. K., Rosenstock, J., Wadden, T. A., Wharton, S., Yokote, K., & Kushner, R. F. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism, 24(8), 1553–1564. https://doi.org/10.1111/dom.14725
Crawford, R. (1980). Healthism and the medicalization of everyday life. International Journal of Health Services, 10(3), 365–388. https://doi.org/10.2190/3H2H-3XJN-3KAY-G9NY
Han, S. H., Safeek, R., Ockerman, K., &... (2024). Public Interest in the Off-Label Use of Glucagon-like Peptide 1 Agonists (Ozempic) for Cosmetic Weight Loss: A Google Trends Analysis. Aesthetic Surgery Journal, 44(1), 84-91. https://doi.org/10.1093/asj/sjad211
Volpp, K. G., & Ali, M. K. (2023). What the viral popularity of GLP-1 receptor agonists means for patients. JAMA, 329(22), 1913–1914. https://doi.org/10.1001/jama.2023.7919
Weber, M. (2001). The Protestant ethic and the spirit of capitalism (T. Parsons, Trans.). Routledge.
Foucault, M. (1973). The Birth of the Clinic: An Archaeology of Medical Perception. Pantheon Books.
Lupton, D. (2016). The Quantified Self. Polity Press.
Marmor, T., & Oberlander, J. (2012). From HMOs to ACOs: The quest for the Holy Grail in US health policy. Journal of General Internal Medicine, 27(9), 1215–1218. https://doi.org/10.1007/s11606-012-2074-3
Sharon, T. (2017). The Googlization of health research: from disruptive innovation to disruptive ethics. Personalized Medicine, 14(3), 263-274. https://doi.org/10.2217/pme-2017-0023
Spaulding, A., Zhao, Y. J., & Haley, H. (2023). Telemedicine and the Direct-to-Consumer Market for Weight Loss Medications: Opportunities and Regulatory Challenges. Health Policy and Technology, 12(4), 100725
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Jakub Klepacz, Radosław Swędrak, Zuzanna Dobrakowska
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
